AZ's XigDuo gets European nod, but it's the US that counts
This article was originally published in Scrip
Executive Summary
Combination diabetes drug XigDuo (dapagliflozin and metformin), developed as part of AstraZeneca and Bristol-Myers Squibb's now defunct joint venture (scripintelligence.com, 19 December 2013), has received final approval in Europe. But the win means little unless AstraZeneca, now marketing the drug alone, can beat rival Johnson & Johnson to have the first fixed-dose combination approval in the US.